 AstraZeneca PLC LSE:AZN said its Tezspire treatment has been approved in Japan for severe bronchial asthma where high-dose traditional corticosteroids dont work. It is the third approval in a matter of weeks for the product, a potential challenger to market leader Dupxient. 